


Showcasing research from Plinio Innocenzi's LMNT lab at University of Sassari, Italy (cover art by Matteo Poddighe).

Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanoparticles

In this work, L. Stagi and co-authors explore the potential of an L-lysine-derived polymeric nanoparticle as an antiviral against SARS-CoV-2. Hyperbranched polylysine nanoparticles, synthesized by thermal polymerization and catalyzed by boric acid, effectively inhibit SARS-CoV-2 replication with a good *in vitro* safety profile. The virucidal activity is associated with the size and charge of the nanomaterial, promoting electrostatic interaction with the viral surface being only slightly larger than the size of the virions. The low-cost production and ease of synthesis strongly support the development of such novel nanomaterials as a tool for potential treatments of COVID-19 and, more generally, as broad-spectrum antivirals.

As featured in:



See Plinio Innocenzi *et al.*,
Nanoscale, 2021, **13**, 16465.



Cite this: *Nanoscale*, 2021, **13**, 16465

Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanopolymers†

Luigi Stagi,^a Davide De Forni,^b Luca Malfatti,^a Francesca Caboi,^c Andrea Salis,^d Barbara Poddesu,^b Giulia Cugia,^b Franco Lori,^b Grazia Galleri^e and Plinio Innocenzi^{*,a}

The coronavirus pandemic (COVID-19) had spread rapidly since December 2019, when it was first identified in Wuhan, China. As of April 2021, more than 130 million cases have been confirmed, with more than 3 million deaths, making it one of the deadliest pandemics in history. Different approaches must be put in place to confront a new pandemic: community-based behaviours (*i.e.*, isolation and social distancing), antiviral treatments, and vaccines. Although behaviour-based actions have produced significant benefits and several efficacious vaccines are now available, there is still an urgent need for treatment options. Remdesivir represents the first antiviral drug approved by the Food and Drug Administration for COVID-19 but has several limitations in terms of safety and treatment benefits. There is still a strong request for other effective, safe, and broad-spectrum antiviral systems in light of future emergent coronaviruses. Here, we describe a polymeric nanomaterial derived from L-lysine, with an antiviral activity against SARS-CoV-2 associated with a good safety profile *in vitro*. Nanoparticles of hyperbranched polylysine, synthesized by L-lysine's thermal polymerization catalyzed by boric acid, effectively inhibit the SARS-CoV-2 replication. The virucidal activity is associated with the charge and dimension of the nanomaterial, favouring the electrostatic interaction with the viral surface being only slightly larger than the virions' dimensions. Low-cost production and easiness of synthesis strongly support the further development of such innovative nanomaterials as a tool for potential treatments of COVID-19 and, in general, as broad-spectrum antivirals.

Received 9th June 2021,
Accepted 23rd August 2021
DOI: 10.1039/d1nr03745e
rsc.li/nanoscale

Introduction

The worldwide emergency created by the COVID-19 outbreak has mobilized the research to explore new solutions for vaccines and therapeutic agents against SARS-CoV-2.¹ A significant challenge to face is the virus capability of genetic mutations, which could hamper the development of effective vaccines for all the possible variants mostly governed by mutations of its spike glycoprotein. Different SARS-CoV-2 variants are circulating globally: B.1.1.7 in the United Kingdom (UK); B.1.351 in South Africa; and P.1 in Brazil.² These variants

present mutations in the receptor binding domain of the spike protein; different studies have indicated that one of the spike protein mutations (E484K, shared by B.1.351 and P.1 variants) may affect the neutralization by some polyclonal and monoclonal antibodies.^{3,4}

It is, therefore, crucial to produce broad-spectrum active antiviral systems.⁵ The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by the lack of effective antiviral treatments against SARS-CoV-2. Remdesivir represents the first treatment approved by the Food and Drug Administration for COVID-19;^{4,3} it has been shown to reduce the hospitalization time but proved to provide only a marginal benefit for patients with severe COVID-19 disease.⁶ Moreover, it is not routinely recommended for patients who require mechanical ventilation due to the lack of data showing benefit at this advanced stage of the disease.^{7–9,32} Remdesivir is an intravenous drug, requiring treatment to be administered in the hospital, and can cause adverse effects such as gastrointestinal symptoms (*e.g.*, nausea), elevated transaminase levels, an increase in prothrombin time, and hypersensitivity reactions. Innovative drugs for effective and safe treatments need to be also developed in the light of possible future pandemics.

^aLaboratorio di Scienza dei Materiali e Nanotecnologie (LMNT), Dipartimento di Chimica e Farmacia, CR-INSTM, Università di Sassari, Via Vienna 2, 07041 Sassari, Italy. E-mail: plinio@uniss.it

^bViroStatics srl, Viale Umberto I, 46, 07100 Sassari, Italy

^cLaboratorio NMR e Tecnologie Bioanalitiche, Sardegna Ricerche, Parco Scientifico e Tecnologico della Sardegna, 09010 Pula, CA, Italy

^dDipartimento di Scienze Chimiche e Geologiche, Università di Cagliari, Cittadella Universitaria, SS 554 bivio Sestu, 09042 Monserrato, CA, Italy

^eDipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Viale S. Pietro 8, 07100 Sassari, Italy

†Electronic supplementary information (ESI) available. See DOI: 10.1039/d1nr03745e



Alternative methods based on nanomaterials and nanoformulations¹⁰ have drawn attention to suppressing the virus spread with a particular emphasis on sanitizing contaminated surfaces.¹¹ Fewer efforts have been dedicated to investigating nanomaterials and nanostructures as antiviral systems to be potentially applied *in vivo*.¹² A few nanosystems such as polymeric nanoparticles covered by a liposome shell modified with antibodies and ligands,¹³ metal nanoparticle composites,¹⁴ graphene¹⁵ and graphene oxide¹⁶ and cross-linked peptides¹⁷ have been proposed as potential antiviral systems for SARS-CoV-2.

The first requirement nanomaterials must satisfy as antibacterial or antiviral systems is the lack of cytotoxicity. Carbon nanomaterials are one of the main candidates to be used as antivirals because several independent studies have demonstrated low cytotoxicity *in vitro* in different cell lines.^{18–20} Within the family of carbon nanomaterials, fullerenes,²¹ graphene,^{22,23} graphene oxide²⁴ and carbon dots^{25,26} have shown antiviral properties and have been tested against different types of viruses, including coronaviruses.^{27,28} Fullerenes exhibit an antiviral activity mainly under UV illumination *via* the production of reactive oxygen species,²⁹ while the interactions of graphene and graphene oxide with viruses are complex, owing to the antiviral properties being associated with wrapping, trapping or physical disruption through the sharp-edged structure.³⁰ However, the dimensions of graphene sheets and the difficulty in achieving precise control of surface functionalization, number and dimension of layers, represent severe limitations.

Other candidates as antiviral nanomaterials are carbon dots (C-dots).³¹ C-dots are characterized by dimensions smaller than 10 nm and an intense emission. In particular, carbon nanoparticles are potentially attractive as virucidal systems because they can interfere with the virus capability to enter the cells. *In vitro* experiments have shown that functional carbon dots inhibit host cells' infection from HCoV-229E coronavirus and HIV-1.^{22,32} On the other hand, C-dots are obtained by carbonising organic precursors, which makes the real control of the intimate structure extremely difficult. Therefore, the drawback of C-dots is that, in most cases, they are a kind of “black box” formed by molecules of different nature and dimensions or having a graphitic core which does not make them, at this stage of knowledge, a good candidate for developing medical drugs. An alternative route to carbon dots and carbon quantum dots as antiviral systems is nanopolymeric materials. They are characterized by a polymeric and flexible structure with dimensions close to, or slightly larger than the viral particle and could interfere with their replicative cycle. The antiviral activity of graphene sheets has shown that the dimensions can be critical to inhibit by physical wrapping of the viruses, thus limiting their capability to enter the cells. The other parameter which appears very critical is surface charge. An effective design of antiviral nanomaterials should be built on the careful control of composition, shape, dimension, and surface charge of the nanostructures.

Polylysine in the form of poly-L-lysine and poly-D-lysine is characterized by a linear polymeric structure and a highly posi-

tive surface charge. Polylysines have shown to possess an inhibitory effect in the replication of RNA and DNA viruses such as HIV-1 and influenza A virus.^{33,34} The antiviral activity and also the cytotoxicity of polylysines increase with the molecular weight. The antiviral activity has been attributed to the inhibition of the virus binding to the cells. These results suggest that a possible antiviral polymeric material should use the positive surface charge of polylysine, while a branched structure should offer the advantage of a higher interaction with the virus at the same nanoscale. Following this general idea, we have tested the antiviral properties of hyperbranched polymeric nanomaterials obtained by boric acid-catalyzed thermal polymerization of L-lysine against the SARS-CoV-2 virus. Experimental data suggest that the nanopolymer antiviral activity prevents the entry of the virus to the cells without being cytotoxic. Polylysine hyperbranched nanopolymers, as suggested by the present study, represent a promising antiviral system whose potentialities worth being further exploited.³⁵

Experimental methods

Nanopolymer preparation

L-Lysine derived nanoparticles have been synthesized by a thermal polymerization method. Commercial L-lysine ((S)-2,6-diaminocaproic acid) powder (Sigma-Aldrich, crystallized, ≥98.0% (NT), $\text{H}_2\text{N}(\text{CH}_2)_4\text{CH}(\text{NH}_2)\text{CO}_2\text{H}$) was placed in a ceramic crucible and heated up to 240 °C for 5 h and allowed to cool down to 20 °C before any further treatment. After the thermal treatment, the obtained brown-black solid was dispersed in Milli-Q water, sonicated for 15 min and then centrifuged at 9000 rpm for 20 min. The supernatant was collected and dialyzed against water for 24 h using a dialysis tube (benzoylated, avg. flat width 32 mm (1.27 in.), replacing the water every 12 h. Then, the resulting nanomaterials were freeze-dried for 24 h and kept at 4 °C before characterization.

Lysine hyperbranched nanopolymers were prepared as follows: boric acid (H_3BO_3) (Carlo Erba) and L-lysine powders were mixed in a mortar and treated at 240 °C for 5 h in air. The obtained compound was sonicated, dialyzed and freeze-dried according to the procedure reported for lysine nanoparticles. L-lysine- H_3BO_3 derived nanopolymers were stored at 4 °C before characterization.

Materials characterization

Transmission electron microscopy (TEM) bright-field images were obtained by using an FEI TECNAI 200 TEM operating at 200 kV with field emission electron guns. Before analysis, the carbon nanomaterials were dispersed in ethanol and ultrasonicated for 10 minutes. Afterward, the solutions containing the carbon nanomaterials were cast on grids made by Cu and covered with an ultrathin layer of carbon (nominally of 3 nm) mounted on a lacey carbon film. After drying at room temperature, the grids were directly used for the measures. The particle size was estimated by measuring at least 10 different particles on 5 images taken from different areas of the grid.



Attenuated total reflectance-Fourier-transform infrared (ATR-FTIR) analysis was carried out using an ATR accessory coupled with an infrared Vertex 70 interferometer (Bruker). The ATR spectra were recorded in the 4000–400 cm^{-1} range with a 4 cm^{-1} resolution.

UV-Vis absorption spectra were recorded using a Nicolet Evolution 300 UV-Vis spectrophotometer (Thermo Fisher) with a bandwidth of 1.5 nm. *In situ* Fourier-transform infrared spectra of sample powders in potassium bromide (KBr, IR 99%, Sigma) were recorded in an electrical heating jacket in a transmission geometry (Specac).

Fluorescence spectroscopy measurements were performed on a Horiba Jobin Yvon Fluoromax-3. Typically, 3D PL maps of aqueous solutions were recorded from 200 nm to 600 nm. The same spectrofluorometer and identical measurement settings were used in all the cases for a simple comparison of the obtained data. Photoluminescence quantum yield (QY) measurements have been performed using a quanta-φ (HORIBA) integrating sphere accessory, attached to a “NanoLog” Horiba Jobin Yvon spectrofluorometer.

X-ray diffraction (XRD) patterns were collected using a SmartLab X-ray powder diffractometer (Rigaku, Tokyo, Japan) in the Bragg-Brentano geometry with Cu $K\alpha$ radiation ($\lambda = 1.54178 \text{ \AA}$) and a graphite monochromator in the diffracted beam.

^1H NMR spectra were recorded at 25 °C on a Bruker Avance III 400 MHz spectrometer. Deuterium Oxide (D_2O) + Tetramethylsilane (TMS, 0.05% v/v) was used as the solvent. Deuterium oxide 99.9 atom % D, containing 0.05 wt% 3-(trimethylsilyl)propionic-2,2,3,3- d_4 acid sodium salt was purchased from Sigma-Aldrich. The samples were dissolved in 0.6 ml of D_2O and transferred to a 5 mm NMR sample tube. TMS, used as an internal standard, was calibrated as $\delta = 0.00$ ppm. The experimental parameters were: ^1H NMR: Pulse angle of 90°, acquisition time of 2.5 s, 512 repetitions and spectral width of 12 ppm.

The degree of branching (DB) and the average number of branches (ANB) have been calculated using the integrals of the different structural units in the ^1H spectra using the formulas:³³

$$\text{DB} = \frac{D + T}{D + L + T} = \frac{D + T}{D + L_\alpha + L_e + T} \quad (1)$$

and

$$\text{ANB} = \frac{D}{D + L} \quad (2)$$

with D being the dendritic units, T the terminal structural units, L_α the N^α -linked linear units, and L_e the N^e -linked linear units (see SI 1†).

Zeta potential (ζ) and hydrodynamic diameter (size) of HPN solutions were measured using a Zetasizer Nano ZSP instrument (Malvern Instruments) in the backscatter configuration ($\theta = 173^\circ$; laser wavelength of $\lambda = 633$ nm). The scattering cell temperature was fixed at 298 K, and the data were analyzed using the Zetasizer software 7.03 version. The samples were

prepared by dissolving solid samples in Milli-Q water (1 mg mL^{-1}). The samples were left under rotation for one hour at 25 °C before analysis. All measurements were carried out at least in triplicate.

Viral isolate

The human 2019-nCoV strain 2019-nCoV/Italy-INMI1 was isolated in Italy (ex-China) from a sample collected on January 29, 2020, from Istituto Lazzaro Spallanzani, Rome, Italy.³⁶

Cell line

Cytotoxicity and antiviral activity of the drugs were studied in Vero E6 cells (*Cercopithecus aethiops*, kidney, ATCC CRL-1586). The cell line was maintained in DMEM supplemented with 1% glutamine, 1% penicillin/streptomycin and 10% fetal bovine serum, FBS (complete medium).

Cytotoxicity assay

A cytotoxicity experiment was performed in parallel with the antiviral assay, using cells from the same passage. Exponentially growing Vero E6 cells were seeded into a 96-well plate at 1×10^5 cells per mL in a complete medium, 24 hours later the cells were exposed to different concentrations of drugs in the complete medium (2% FBS, as in the antiviral activity assay) for 72 hours. The HPNs were resuspended in DMSO and sonicated for 15 minutes. Compound dilutions were performed in a culture medium. Remdesivir was included as a reference drug.

The cytotoxic effect was evaluated using the MTS colorimetric assay (Promega) and confirmed through observation of the cell monolayer at the microscope. A cytotoxic concentration of 50% (CC_{50}) was calculated through interpolation of the dose-response curves generated using Magellan™ software. The tests with SARS-CoV2 have been performed in a Biosafety Level 3 (BSL3) facility which is located in the science park of Porto Conte Ricerche (Alghero, Italy).

Antiviral activity assay

Exponentially growing Vero E6 cells were seeded into a 96-well plate at their optimal density in the complete medium, and 24 hours later the cells were exposed to different concentrations of drugs. Then, the cells were infected with SARS-CoV-2 (multiplicity of infection 0.01) and cultured for 72 hours. Two replicates for each concentration point were examined. Two different experiments were performed. At the end of the incubation period, the antiviral activity was examined both through the ELISA assay (Sino Biological, quantifying SARS-CoV-2 nucleoprotein) and the cytopathic effect observation using a microscope. An inhibitory concentration of 50% (IC_{50}) value was calculated.

Time-of-addition experiments

Vero E6 cells (1×10^5 cells per mL) were seeded into 96-well plates and treated with the compound ($500 \mu\text{g mL}^{-1}$) at different stages of virus infection. For full-time treatment, the cells were pre-treated with the compound for 1 h prior to virus



infection at 37 °C, followed by virus adsorption for 1 h in the presence of the molecule. Then, the cells were washed and further cultured at 37 °C with the molecule-containing medium until the end of the experiment. For pre-adsorption treatment, the agent was added to the cells for 1 h at 37 °C before virus infection and maintained during virus adsorption. Then, the mixture was replaced with a fresh medium without molecules until the end of the experiment. For the post-adsorption assay, the drug-containing medium was added to the cells only after virus adsorption and maintained until the end of the experiment. Uninfected cells were included in all experimental settings to exclude possible drug-toxicity CPE. For all the experimental groups, the cells were infected with a multiplicity of infection 0.01 and adsorption was performed for 1 h at 37 °C. At the end of the incubation period (72 hours), antiviral activity was examined through the ELISA assay.

All conditions were tested in duplicate.

Flow cytometry

Vero E6 cells were grown in a tissue culture flask of 25 cm² until ~80% confluent, then treated with nanoparticles at 250 µg mL⁻¹ for 24 hours. Untreated cells were used as the control. Then, the cells were detached and resuspended in ice cold PBS for flow cytometry analysis.

The samples have been acquired on a FACSCanto flow cytometer (BD Biosciences) and data analysis was performed using the BD FACSDiva software program.

Vero E6 cells were selected, gating out dead cells, and both percentages and mean fluorescence intensity (MFI) of fluorescent HPN treated cells were evaluated (FITC channel). 10 000 events were collected for each experiment.

When determining the internalization of nanoparticles, the cells were treated with trypan blue 0.025% for 5 minutes at room temperature before acquisition. Flow cytometry images were generated with FCS Express software.

Nanoparticle uptake for confocal microscopy

Vero E6 cells were grown in 35 mm coverslips directly into a 6-well plate until ~60% confluent, then treated with nanoparticles at 250 µg mL⁻¹ for 24 hours. Untreated cells were used as the control. The cells were washed in PBS and fixed with paraformaldehyde 4% for 15 minutes, then washed with PBS/1% albumin, then PBS only and finally water. Coverslips were then dehydrated and mounted on a slide with 50% glycerol under a cover slip, and images were acquired using a Leica TCS SP5 confocal microscopy, with LAS lite 170 image software.

Results and discussion

Hyperbranched nanopolymer structure and properties

Lysine, an amino acid commonly found in protein-rich foods, such as eggs and meat, has been selected as a natural precursor to obtain highly biocompatible polymeric nanomaterials.

Different types of carbon dots with a graphitic core have been also successfully synthesised *via* bottom-up routes using lysine in previous works.^{37,38} L-Lysine is a versatile precursor that can form dendrimers and hyperbranched polymeric structures upon controlled thermal polymerization.^{39,40} It can be polymerized to hyperbranched polylysine through the polyamidation reactions.⁴¹ Hyperbranched polymers (HP) are defined as highly branched macromolecules that have an irregular branching and structure.⁴² HP synthesized from amino acids offer several advantages with respect to linear peptides in terms of solubility, biocompatibility, and enhanced proteolytic stability.⁴³ For these reasons, they are currently under the highlight for developing therapeutic applications.⁴⁴

In general, the formation of hyperbranched lysine polymers without employing any amidation catalyst or protective groups requires several synthesis steps. In the present work, we have used a simple approach to produce nanoparticles formed by hyperbranched polylysine (hyperbranched polylysine nanoparticles, HPNs) *via* a thermal polymerization of a mixture of L-lysine and boric acid (H₃BO₃).

We have synthesised two distinct nanopolymers *via* the thermal treatment of L-lysine,⁴⁵ the first one employing only pure L-lysine as the precursor and the second one by using a L-lysine–H₃BO₃ mixture with boric acid as the catalyst. The two nanomaterials, because of the addition of boric acid, differ in terms of dimension, branching and surface charge. This difference has been reflected in a much different antiviral response, with lysine-only-materials which do not exhibit any antiviral activity (*vide infra*). We have, therefore, concentrated our attention on the nanomaterial obtained by the mixture of L-lysine and H₃BO₃.

To understand the effect of the thermal treatment on the derived nanomaterials, we used FTIR *in situ* spectroscopy to monitor the structural changes as a function of the temperature. Fig. 1a shows the temperature–wavenumber–intensity infrared graph in the 1800–1450 cm⁻¹ range of the L-lysine–H₃BO₃ mixture during thermal treatment in air from 25 °C up to 240 °C.

The FTIR data collected *in situ* at increasing temperatures show that the lysine–H₃BO₃ (Fig. 1b) system undergoes an amidation reaction between 185 and 225 °C in accordance with Differential Scanning Calorimetry (DSC) data (Fig. 1c). The –COO⁻ stretching band at 1580 cm⁻¹ decreases in intensity with the increase in the temperature to transform into the C=O stretching band of amide I peaking at around 1654 cm⁻¹. This process gives the formation of oligoamides *via* one-step growth polycondensation of L-lysine in the presence of boric acid by thermal treatment at 240 °C.⁴⁶ ¹H NMR (Fig. S1–S4†) well support the formation of a hyperbranched polylysine structure (Fig. S5†) in accordance with the literature.^{32,34} The calculated degree of branching, DB, and an average number of branches, ANB, are 0.4 and 0.13, respectively. The polycondensation reactions give spherical-like nanoparticles whose dimensions are within the 200–300 nm range (Fig. 2). The nanoparticles can be dispersed in water and






Fig. 1 (a) *In situ* FTIR spectra in the 1800–1475 cm⁻¹ range during thermal treatment of the L-lysine–H₃BO₃ mixture (1 : 1 molar ratio) from 25 to 250 °C. The absorbance is reported in the false colour scale. (b) FTIR spectra of pure L-lysine and L-lysine–H₃BO₃ mixture in the 4000–400 cm⁻¹ range (blue and black line, respectively). (c) DSC analysis of the L-lysine–H₃BO₃ mixture (1 : 1 molar ratio) from 25 to 500 °C (blue line). The black line shows the thermal ramp with a 20 min dwelling time at 180 °C.

DMSO solvent up to the concentrations used for the *in vitro* tests.

Fig. 2a shows the UV–Vis absorption spectra of pure L-lysine (black line) and HPNs (red line) in water. The spectra are characterized by an intense absorption band in the deep UV, at 205 nm, which is assigned to π – π^* transitions. At higher wavelengths, a weak absorption band peaking at 270 nm, which has been previously attributed to lysine aggregates, is observed.⁴⁷ The HPNs are fluorescent with an emission in the blue region. Fig. 2b shows the three-dimensional (3D) fluorescence spectra [excitation (*y*)–emission (*x*)–intensity (*z*)] of HPNs in water with an excitation-dependent emission response. The nanomaterials exhibit a broad emission peaked at 450 nm under excitation at 370 nm with a QY efficiency of 4.5%. By comparing the HPN optical properties with those of the L-lysine precursor,⁴⁰ the emission in the blue region appears characteristic of the amino acid (Fig. S6†) which has an emission maximum at around 440 nm under excitation at 360 nm. The fluorescence of such a nanomaterial represents an intrinsic advantage because it can be also used at the same time for bioimaging to follow its interactions with the cells (*vide infra*).

The TEM images of the HPNs reveal the formation of quasi-spherical structures (Fig. 2c), in the \approx 150–200 nm range. The electronic contrast is very low which does not allow precise identification of the particle boundary. Moreover, the particles appear completely amorphous with no evidence of any crystalline phase, as observed in different HPNs and supported by X-ray diffraction analysis (Fig. S7†). These results are compatible with the formation of interconnected polymeric structures with a low degree of densification. Fig. 2d shows the Dynamic Light Scattering (DLS) measurement of the HPNs in water. The particle distribution is well simulated by a Gaussian curve with a maximum at around 300 nm.

Another characterization of the hyperbranched polymeric nanoparticles regards the nature of the surface charge. The analysis by zeta potential has shown that the particles have a $+20 \pm 2$ mV charge, in accordance with similar values measured for carbon dots.⁴⁸

Cytotoxicity

Cytotoxicity and antiviral efficacy against SARS-CoV-2 of the HPNs have been assessed in African green monkey Vero E6 cells. Remdesivir is an intravenous prodrug of an adenosine






Fig. 2 (a) UV-Vis absorption spectra of lysine (black line) (0.01 M) and carbon nanomaterials (red line) in water ($250 \mu\text{g mL}^{-1}$). (b) The excitation (y axis)–emission (x axis)–intensity (false colour scale) fluorescence map of the carbon nanomaterials in water (0.25 mg mL^{-1}). (c) Representative bright-field TEM image of HPNs. (d) Dynamic light scattering of the HPNs (black spots) in water ($250 \mu\text{g mL}^{-1}$). The bright areas are holes in the TEM grid.

analog, binding to the viral RNA-dependent RNA polymerase and inhibiting SARS-CoV-2 replication through premature termination of RNA transcription and has been used in the present work as a reference drug, as it shows antiviral activity *in vitro* against the new coronavirus⁴⁹ and represents the first treatment approved by the Food and Drug Administration for COVID-19.⁵⁰

To investigate the extent of HPN biocompatibility, we have performed standard MTS cytotoxicity assays. Soluble tetrazolium salts, such as 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), are reduced by cellular nicotinamide adenine dinucleotide (phosphate)-dependent oxidoreductase enzymes in the presence of an intermediate electron acceptor (phenazine ethosulfate) to produce (producing) a formazan derivative that is quantified by spectrophotometry.

This product reflects the metabolic activity and thus viability of cells and, hence, can be used to determine a toxic dose of a substance. Indeed, it has been recently published a standard

dedicated to nanomaterials using the MTS assay as an *in vitro* cytotoxicity assay.⁵¹ Vero E6 cells have been exposed to increasing concentrations (0.5 , 5 , 50 , and $500 \mu\text{g mL}^{-1}$) of HPNs to get the 50% cytotoxic concentration (CC_{50}) value; the data have been compared with the reference drug remdesivir⁵² (Table 1).

$500 \mu\text{g mL}^{-1}$ is the highest dose that could be tested because of DMSO solvent concentration limits in cell culture. The results show that HPNs are not cytotoxic up to the maximum tested dose, with a $\text{CC}_{50} > 500 \mu\text{g mL}^{-1}$, in accordance with previous biocompatibility tests for carbon dots.¹⁶ The reference drug remdesivir has a CC_{50} value of $> 60 \mu\text{g mL}^{-1}$ and is more cytotoxic than HPNs because it produces a similar mean loss of cell viability at the highest test dose, but at 8-times lower concentration compared to HPNs. Fig. 3 shows the cytotoxicity curves of HPNs (left) and remdesivir (right).

Antiviral activity

The antiviral assay was performed in parallel with the cytotoxicity experiments, using the SARS-CoV-2 permissive cell line

Table 1 Cytotoxicity data (expressed as % viability compared to control, mean and standard deviation) obtained in MTS assay

Remdesivir		HPNs	
Concentration ($\mu\text{g mL}^{-1}$)	Cytotoxicity (% cell viability, compared to untreated control)	Concentration ($\mu\text{g mL}^{-1}$)	Cytotoxicity (% cell viability, compared to untreated control)
60	82.1 ± 2.2	500	85.8 ± 2.9
12	98.9 ± 6.7	50	102.5 ± 2.8
2.4	94.1 ± 1.0	5	99.1 ± 1.9
0.5	104.2 ± 9.4	0.5	98.8 ± 1.1






Fig. 3 Cytotoxicity of HPNs (left) and reference drug remdesivir (right). The lines are a guide to the eye.

Vero E6 from the same culture passage. The cells have been seeded into 96-well plates and exposed to different concentrations of remdesivir and HPNs. Cells have been then infected with SARS-CoV-2 (multiplicity of infection, m.o.i, 0.01) and cultured for 72 hours. At the end of the incubation period, viral replication has been examined through ELISA assay, quantifying SARS-CoV-2 nucleoprotein. The virus-induced cytopathic effect (CPE) resulted in detached cells, as monitored by light microscopy. Antiviral efficacy data (*i.e.*, SARS-CoV-2 nucleocapsid protein, NC, expressed as % of control, mean and standard deviation) obtained in the ELISA assay are listed in Table 2.

HPNs effectively reduce SARS-CoV-2 viral replication, with a 50% inhibitory concentration (IC_{50}) value of $125 \mu\text{g mL}^{-1}$. Remdesivir has been used as the control of viral infectivity inhibition and has shown an IC_{50} of $1.9 \mu\text{g mL}^{-1}$, in line with the results obtained by other research groups employing different readout methodologies.⁵³ Fig. 4 shows the dose-response curves of HPNs (left) and remdesivir (right).

Control experiments have been performed testing the antiviral activity of polylysine nanopolymers obtained without the use of boric acid as a catalyst. They have a smaller zeta potential, not higher than +6 mV, and a larger dimension in comparison with HPNs and do not show any antiviral activity (Fig. S8 and Table S1†).

The virus infection positive control has shown marked effects on cell morphology (Fig. 5b) compared to the uninfected control (Fig. 5a). HPNs have shown a degree of protection from cytopathic damage at effective concentrations. The pictures taken on the cells during treatment with HPNs at $2 \times IC_{50}$ show that it effectively restores the Vero E6 cell monolayer (Fig. 5c).

Time of addition

Previous reports suggest that the SARS-CoV-2 virus binds to the angiotensin converting enzyme 2 (ACE2) receptor with its spike protein. The virus size is around 60–140 nm.⁵⁴

Table 2 Antiviral activity data of test compounds at the different concentrations, *i.e.*, % viral nucleocapsid protein, NC, compared to untreated infected control (=100%)

Remdesivir		HPNs	
Concentration ($\mu\text{g mL}^{-1}$)	Antiviral activity (% viral NC protein, compared to untreated control)	Concentration ($\mu\text{g mL}^{-1}$)	Antiviral activity (% viral NC protein, compared to untreated control)
6	14 ± 7	500	14 ± 6
1.2	73 ± 9	50	79 ± 41
0.24	96 ± 10	5	95 ± 19
0.05	107 ± 23	0.5	94 ± 9




Fig. 4 Effect of the nanomaterial on the SARS-CoV-2 replication (left) and control remdesivir drug (right). The lines are a guide to the eye.





Fig. 5 Optical images of the Vero E6 monolayer: (a) uninfected control, (b) infected with SARS-CoV-2, and (c) infected with SARS-CoV-2 and treated with HPNs at $250 \mu\text{g mL}^{-1}$. Optical microscope image at 50 \times magnification.

Most of the reported carbon dots exhibit their antiviral activity interfering with the early stage of viral infection by altering the viral surface proteins. Surface-functionalized carbon dots with amine or boronic acid functional groups effectively inhibit the host-cell entry of herpes simplex virus type 1.⁵⁵ Curcumin derived carbon dots can block infection at a very early stage of viral entry due to viral aggregation and inactivation caused by electrostatic interaction of positively charged carbon dots.²¹ Also, curcumin carbon dots have shown to slow down the production of negative RNA strands in the porcine epidemic diarrhea virus.²¹ Viral inhibition could also be derived from hindering budding and detachment steps when the progeny of the virus is budding from the host cells.²¹ Inhibition of another human coronavirus HCoV-229E entry and viral replication was achieved with carbon dots.²² Huang *et al.* showed that carbon dots inhibited viral entry of both enveloped (flaviviruses such as Zika and dengue) and non-enveloped viruses (*e.g.* adenovirus-associated virus) by binding directly to viral surface proteins and hindering the first step of viral attachment to the host cell.⁵⁶ We, therefore, have asked ourselves whether similar mechanisms can explain the antiviral activity of HPNs. Hence, we have performed a time-of-addition experiment to explore which step in the viral life cycle is blocked by these nanomaterials.

For the full-time treatment, cells have been pre-treated with HPNs (a concentration of $4 \times \text{IC}_{50}$ was selected for this experiment, *i.e.* $500 \mu\text{g mL}^{-1}$) for 1 h prior to virus infection at 37°C , followed by virus adsorption for 1 h in the presence of HPNs. Then, cells have been washed and further cultured at 37°C with the HPN-containing medium until the end of the experiment. To examine whether the substance could block viral attachment and entry, a pre-adsorption treatment has been performed, where HPNs have been added to the cells for 1 h at 37°C before virus infection and maintained during virus adsorption. Then, the mixture has been replaced with a fresh medium without HPNs until the end of the experiment. To examine the antiviral effect during post-entry steps, such as genome translation and replication, virion assembly and virion release from the cells, a post-adsorption assay has been carried out, in which the HPN-containing medium has been added to cells only after virus adsorption and maintained until the experiment's end.

The full-time treatment with HPNs has resulted in a complete viral replication inhibition, measured by quantification

of the viral nucleocapsid protein by ELISA assay. The molecule did not show the same degree of protection in the pre-adsorption treatment, as viral replication inhibition was 26% compared to untreated control; in the post-adsorption treatment, inhibition of viral replication was 72% compared to untreated control (Fig. 6). The results suggest that HPN may act at different stages of the SARS-CoV-2 life cycle. No compound-related cytotoxic effect has been observed on uninfected cells in all experimental settings (not shown in data).

Nanoparticle uptake kinetics

To confirm whether HPNs could penetrate the host cell and, therefore, have the potential to exhibit antiviral activity in post-entry steps, we have investigated the nanoparticle uptake into the cells, performing a series of experiments in which Vero E6 cells have been incubated for 6 and 24 hours in growth medium containing effective concentrations of HPNs ($2 \times \text{IC}_{50}$, $250 \mu\text{g mL}^{-1}$ or $4 \times \text{IC}_{50}$, $500 \mu\text{g mL}^{-1}$). The resulting fluorescence per cell has been evaluated by flow cytometry. Fluorescence intensity overlapped when cells were pulsed with the HPNs for 6 or 24 hours (Fig. 7a), indicating efficient nanoparticle entry into the cells for shorter or longer incubation times, at concentrations compatible with a demonstrated antiviral efficacy. We have also demonstrated that the HPNs are taken up by the cells in a dose-dependent manner (Fig. 7b and c).

To verify whether the hyperbranched nanopolymers are taken up by the cells, trypan blue 0.025% has been employed to quench the fluorescence of molecules external to the cell




Fig. 6 Time-of-addition experiments. Inhibition of viral replication (*i.e.*, production of viral nucleocapsid protein detected through ELISA 72 hours post infection) is shown for full-time treatment, pre-adsorption treatment and post-adsorption treatment.






Fig. 7 (a) Flow cytometry histograms for cells pulsed with $250 \mu\text{g mL}^{-1}$ of the HPNs and analyzed after 6 (blue) and 24 hours (red), and control cells are shown in black. Flow cytometry histograms for cells treated with $250 \mu\text{g mL}^{-1}$ (b) and $500 \mu\text{g mL}^{-1}$ (c) of the nanomaterial for 24 hours; treated cells are shown in red compared to control cells in black.

membrane. Trypan blue is a routinely used counterstain that can quench autofluorescence.^{57,58} After trypan blue treatment, the fluorescence of HPNs is still visible, confirming localization inside the cell (Fig. S9†).

Fluorescence microscopy

Nanoparticle internalization has been confirmed by analyzing Vero E6 cells pulsed with HPNs for 24 hours by means of confocal microscopy.

After 24 h of incubation with $250 \mu\text{g mL}^{-1}$ of HPNs, fluorescent green spots are visible inside the cytoplasm confirming internalization (Fig. 8a and b). Z-Stack and 3D rendering have confirmed that the HPNs are effective inside the cells and not on the cell surface (Fig. 8c and d). There is no evidence of HPNs in the cell nuclei (Fig. 8c).

The plasma membrane represents a highly selective barrier protecting living cells and limiting the entry and exit of large macromolecules. The capability of HPNs to rapidly and effec-




Fig. 8 Confocal microscope images of control (a) and (b) cells pulsed with the nanomaterial at a concentration of $250 \mu\text{g mL}^{-1}$ for 24 hours; (c) 3D projection of fluorescence distribution within the cell; (d) 3D rendering through side projections of confocal Z-stack confirming the presence of the nanoparticles (green spots). The slides were analysed using a Leica SP5 confocal microscope.



tively penetrate host cells might represent an advantage over drugs with poor permeability properties. Uptake of the nanoparticles by the cellular systems most probably occurs with a process known as endocytosis.⁵⁹ Further studies will be needed to better elucidate the uptake mechanism of HPNs, to assess whether it is the result of pinocytosis or phagocytosis processes.

To explain the antiviral activity of HPNs, we should consider that SARS-CoV-2 is characterized by the spike (S) glycoprotein⁶⁰ on the outer surface, which plays a critical role in the interaction with antiviral systems and external surfaces.⁶¹ van der Waals and surface charges are the forces that govern the interaction of the virus through the surface-associated active chemical groups, namely carboxylic acid, hydroxyls, amines and carbonyls. Viral particles, in general, have an isoelectric point below 7⁶² and at neutral pH exhibit a negative charge. Highly positively charged polylysine molecules have already shown to have a strong electrostatic interaction with viruses and to be able to inhibit their replication. The same mechanism can be assumed in the present case.^{29,30} The hyperbranched structure favours the interaction with the SARS-CoV-2 spikes through the surface charge; on the other hand, nanopolymers with a lower branching and positive surface charge do not exhibit any antiviral activity.

Besides viral entry inhibition, other mechanisms of antiviral activity can be hypothesised. Other research groups, in fact, have observed that nanomaterials exhibit their antiviral activity against several viruses by several distinct mechanisms interfering at different stages of viral replication, *e.g.* alteration of viral attachment and inhibition step, inhibition/stop of RNA replication (through alteration of enzymes that are needed for viral genome replication), hindering budding and detachment steps.⁶³ As we have demonstrated that HPNs penetrate the cells (Fig. 7 and 8), this suggests that they exhibit antiviral activity not only at the entry-level but also by limiting viral RNA replication or budding of virions. The time-of-addition experiment (Fig. 6) confirms that HPNs may act at different stages of the SARS-CoV-2 life cycle, either acting at viral entry or post-adsorption steps.

Conclusions

In the present work, we have explored a potential antiviral treatment based on hyperbranched nanopolymers. Thermal polymerization of L-lysine catalyzed by boric acid allows hyperbranched nanopolymers to obtain an average dimension of 200 nm and a positive charge. If the polymerization is carried out without boric acid, the final nanopolymer has a less branched structure, smaller positive charge and larger dimension. The L-lysine only nanopolymer has not shown any antiviral activity in contrast of the hyperbranched one.

The hyperbranched polylysine nanoparticles are not cytotoxic up to the maximum tested dose, 500 mg mL⁻¹, while remdesivir, used as a reference drug to test the antiviral properties, is more cytotoxic. The hyperbranched polylysine nano-

particles have shown a remarkable capability to inhibit the SARS-CoV-2 viral replications, with a 50% inhibitory concentration (IC₅₀) value of 125 μg mL⁻¹ and good protection from cytopathic damage. The surface charge of the hyperbranched polylysine nanoparticles may favour the electrostatic interaction with the virus surface, which explains the antiviral activity. Because of the mechanism of action that has been hypothesized, the virucidal effects should be largely independent of the genome of SARS-CoV-2 and, therefore, are the lysine hyperbranched nanopolymers expected to be effective against multiple existing and newly emerging variants.

Besides the potential low cost and easy synthesis, the polymeric hyperbranched nanomaterial derived from L-lysine opens the route for developing new solutions as possible treatments of COVID-19 and in general as broad-spectrum antivirals.

Author contributions

L. S., D. D. F., L. M., and P. I. designed the experiments, analyzed the data and wrote the article; F. L. gave conceptual advice; L. S., D. D. F., B. P., G. C. and G. G. performed the experiments; L. S., D. D. F., F. C., A. S. characterized the materials.

Conflicts of interest

The authors declare no competing interests.

Acknowledgements

This work was supported by the project Nano4Covid from Sardegna Ricerche and the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 87102. Financial support of the MUR FISR2020IP_02620 project, Carepro Covid-19 is gratefully acknowledged. Fondazione Fondazione Centro Servizi alla Persona is gratefully acknowledged for financial support. L. S. gratefully acknowledges Programma Operativo Nazionale (PON) Ricerca e Innovazione 2014–2020 Linea 1 for the financial support. We thank Prof. Claudia Crosio (Department of Biomedical Sciences, University of Sassari, Italy) for her kind support in the acquisition and interpretation of images at the confocal microscope.

References

- 1 C. Liu, Q. Zhou, Y. Li, L. V. Garner, S. P. Watkins, L. J. Carter, J. Smoot, A. C. D. Gregg, A. D. Daniels, S. Jervey and D. Albaiu, *ACS Cent. Sci.*, 2020, **6**, 315–331.
- 2 Centers for Disease Control and Prevention. Science Brief: Emerging SARS-CoV-2 Variants [Cited 2021 January 28].



- Available from: <https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html>.
- 3 Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. Lorenzi, *et al.*, *eLife*, 2020, **9**, e61312.
 - 4 P. C. Resende, J. F. Bezerra, R. H. T. de Vasconcelos, I. Arantes, L. Appolinario, A. C. Mendonca, *et al.*, Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020 [Posted 2021 January 10]. Available from: <https://virological.org/t/spike-e484k-mutation-in-the-first-sars-cov-2-reinfection-case-confirmed-in-brazil-2020/584>.
 - 5 N. Y. Cho and J. S. Glenn, *Nat. Mater.*, 2020, **19**, 813–816.
 - 6 J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, H. Y. Chu, A. Luetkemeyer, S. Kline, *et al.*, *N. Engl. J. Med.*, 2020, **383**, 1813–1826.
 - 7 Y. Wang, D. Zhang, G. Du, *et al.*, *Lancet*, 2020, **395**, 1569–1578.
 - 8 C. D. Spinner, R. L. Gottlieb, G. J. Criner, *et al.*, *J. Am. Med. Assoc.*, 2020, **324**, 1048–1057.
 - 9 J. D. Goldman, D. C. B. Lye, D. S. Hui, *et al.*, *N. Engl. J. Med.*, 2020, **383**, 1827–1837.
 - 10 T. Lammers, A. M. Sofias, R. van der Meel, R. Schifflers, G. Storm, F. Tacke, S. Koschmieder, T. H. Brümmendorf, F. Kiessling and J. M. Metselaar, *Nat. Nanotechnol.*, 2020, **15**, 622–624.
 - 11 S. M. Imani, L. Ladouceur, T. Marshall, R. Maclachlan, L. Soleymani and T. F. Didar, *ACS Nano*, 2020, **14**, 12341–12369.
 - 12 S. Szunerits, A. Barras, M. Khanal, Q. Pagneux and R. Boukherroub, *Molecules*, 2015, **20**, 14051–14081.
 - 13 M. Chen, J. Rosenberg, X. Cai, A. H. Hsuan Lee, J. Shi, M. Nguyen, T. Wignakumar, V. Mirle, A. J. Edozor, J. Fung, J. Scott Donington, K. Shanmugarajah, Y. Lin, E. Chang, G. Randall, P. Penalzoza-MacMaster, B. Tian, M. L. Madariaga and J. Huang, *Matter*, 2021, **4**, 1–24.
 - 14 S. Y. Chang, K. Y. Huang, T. L. Chao, H. C. Kao, Y. H. Pang, L. Lu, C. L. Chiu, H. C. Huang, T. J. R. Cheng, J. M. Fang and P. C. Yang, *Sci. Rep.*, 2021, **11**, 8692.
 - 15 I. S. Donskyi, C. Nie, K. Ludwig, J. Trimpert, R. Ahmed, E. Quaas, K. Achazi, J. Radnik, M. Adeli, R. Haag and K. Osterrieder, *Small*, 2021, **17**, 2007091.
 - 16 M. Altay Unal, F. Bayrakdar, H. Nazir, O. Besbinar, C. Gurcan, N. Lozano, L. M. Arellano, S. Yalcin, O. Panatli, D. Celik, D. Alkaya, A. Agan, L. Fusco, S. S. Yildiz, L. G. Delogu, K. Can Akcali, K. Kostarelos and A. Yilmaze, *Small*, 2021, 2101483.
 - 17 H. Zhao, K. K. W. To, H. Lam, X. Zhou, J. F. W. Chan, Z. Peng, A. C. Y. Lee, J. Cai, W. M. Chan, J. D. Ip, C. C. S. Chan, M. L. Yeung, A. J. Zhang, A. W. H. Chu, S. Jiang and K. Y. Yuen, *Nat. Commun.*, 2021, **12**, 1517.
 - 18 J. Bi, Y. Li, H. Wang, Y. Song, S. Cong, D. Li, D. Zhou, B.-W. Zhu and M. Tan, *New J. Chem.*, 2017, **41**, 8490–8496.
 - 19 J. Yan, S. Hou, Y. Yu, Y. Qiao, T. Xiao, Y. Mei, Z. Zhang, B. Wang, C.-C. Huang, C.-H. Lin and G. Suo, *Colloids Surf., B*, 2018, **171**, 241–249.
 - 20 W. Su, H. Wu, H. Xu, Y. Zhang, Y. Li, X. Li and L. Fan, *Mater. Chem. Front.*, 2020, **4**, 821–836.
 - 21 A. R. Badireddy, J. F. Budarz, S. Chellam and M. R. Wiesner, *Environ. Sci. Technol.*, 2012, **46**, 5963–5970.
 - 22 I. S. Donskyi, W. Azab, J. L. Cuellar-Camacho, G. Guday, A. Lippitz, W. E. S. Unger, K. Osterrieder, M. Adeli and R. Haag, *Nanoscale*, 2019, **11**, 15804–15809.
 - 23 V. Palmieri and M. Papi, *Nano Today*, 2020, **33**, 100883.
 - 24 M. Sametband, I. Kalt, A. Gedanken and R. Sarid, *ACS Appl. Mater. Interfaces*, 2014, **6**, 1228–1235.
 - 25 D. Ting, N. Dong, L. Fang, J. Lu, J. Bi, S. Xiao and H. Han, *ACS Applied Nano Mater.*, 2018, **1**, 5451–5459.
 - 26 A. Loczechin, K. Séron, A. Barras, E. Giovanelli, S. Belouzard, Y.-T. Chen, N. Metzler-Nolte, R. Boukherroub, J. Dubuisson and S. Sabine Szunerits, *ACS Appl. Mater. Interfaces*, 2019, **11**, 42964–42974.
 - 27 P. Innocenzi and L. Stagi, *Chem. Sci.*, 2020, **11**, 6606–6622.
 - 28 Á. Serrano-Aroca, K. Takayama, A. Tuñón-Molina, M. Seyran, S. Sarif Hassan, P. Pal Choudhury, V. N. Uversky, K. Lundstrom, P. Adadi, G. Palù, A. A. A. Aljabali, G. Chauhan, R. Kandimalla, M. M. Tambuwala, A. Lal, T. Mohamed Abd El-Aziz, S. Sherchan, D. Barh, E. M. Redwan, N. G. Bazan, Y. Kumar Mishra, B. D. Uhal and A. Brufsky, *ACS Nano*, 2021, **15**, 8069–8086.
 - 29 J. Kim, H. Lee, J.-Y. Lee, K.-H. Park, W. Kim, J. H. Lee, H.-J. Kang, S. W. Hong, H.-J. Park, S. Lee, J.-H. Lee, H.-D. Park, J. Y. Kim and Y. W. J. Lee, *Appl. Catal., B*, 2020, **270**, 118862.
 - 30 S. Ye, K. Shao, Z. Li, N. Guo, N. Zuo, Q. Li, Z. Lu, L. Chen, Q. He and H. Han, *ACS Appl. Mater. Interfaces*, 2015, **7**, 21571–21579.
 - 31 S. Kotta, H. M. Aldawsari, S. M. Badr-Eldin, N. A. Alhakamy, S. Md, A. B. Nair and P. K. Deb, *Front. Mol. Biosci.*, 2020, **7**, 616575.
 - 32 Y. Y. Aung, A. Novi Kristanti, S. Qamariyah Khairunisa, N. Nasronudin and M. Zakki Fahmi, *ACS Biomater. Sci. Eng.*, 2020, **6**, 4490–4501.
 - 33 M. Hosoya, J. Neyts, N. Yamamoto, D. Schols, R. Smoock, R. Pauwels and E. De Clercq, *Antiviral Chem. Chemother.*, 1991, **2**, 243–248.
 - 34 N. Langeland, L. J. Moore, H. Holmsen and L. Haarr, *J. Gen. Virol.*, 1988, **69**, 1137–1145.
 - 35 P. Innocenzi, L. Stagi, L. Malfatti and D. de Forni, Carbon-based antiviral nanoparticles. *Italian Patent Application n* 102021000009410, 14 April, 2021.
 - 36 Information on Human 2019-nCoV strain 2019-nCoV/Italy-INMI1 available from: <https://www.european-virus-archive.com/virus/human-2019-ncov-strain-2019-ncovitaly-inmi1-clade-v>.
 - 37 E. Arad, S. K. Bhunia, J. Jopp, S. Kolusheva, H. Rapaport and R. L. Jelinek, *Adv. Ther.*, 2018, **1**, 1800006.
 - 38 P. Li, F. Han, W. Cao, G. Zhang, J. Li, J. Zhou, X. Gong, G. Turnbull, W. Shu, X. Lunguo, B. Fang, X. Xing and B. Li, *Appl. Mater. Today*, 2020, **19**, 100601.



- 39 C. Gao and D. Yan, *Prog. Polym. Sci.*, 2004, **29**, 183–275.
- 40 M. Scholl, T. Q. Nguyen, B. Bruchmann and H.-A. Klok, *Macromolecules*, 2007, **40**, 5726–5734.
- 41 M. Scholl, T. Q. Nguyen, B. Bruchmann and H.-A. Klok, *J. Polym. Sci., Part A: Polym. Chem.*, 2007, **45**, 5494–5508.
- 42 Y. Zheng, S. Li, Z. Weng and C. Gao, *Chem. Soc. Rev.*, 2015, **44**, 4091–4130.
- 43 Y. Huang, D. Wang, X. Zhu, D. Yana and R. Chen, *Polym. Chem.*, 2015, **6**, 2794–2812.
- 44 D. Wang, T. Zhao, X. Zhu, D. Yana and W. Wang, *Chem. Soc. Rev.*, 2015, **44**, 4071.
- 45 M. R. Heinrich, D. L. Rohlfing and E. Bugna, *Arch. Biochem. Biophys.*, 1969, **130**, 441–448.
- 46 R. Oliva, M. A. Ortenzi, A. Salvini, A. Papacchini and D. Giomi, *RSC Adv.*, 2017, **7**, 12054–12062.
- 47 L. Homchaudhuri and R. Swaninatham, *Chem. Lett.*, 2001, **8**, 844–845.
- 48 S. Mura, R. Ludmerczki, L. Stagi, S. Garroni, C. M. Carbonaro, P. C. Ricci, M. F. Casula, L. Malfatti and P. Innocenzi, *Sci. Rep.*, 2020, **10**, 4770.
- 49 K.-T. Choy, A. Y.-L. Wong, P. Kaewpreedee, S. F. Sia, D. Chen, K. P. Y. Hui, D. Ka, W. Chu, M. C. W. Chan, P. P.-H. Cheung, X. Huang, M. Peiris and H.-L. Yen, *Antiviral Res.*, 2020, **178**, 104786.
- 50 Food and Drug Administration website, press announcement released on October 22, 2020. Available from: <http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19>.
- 51 International Standard ISO 19007: 2018(E), *Nanotechnologies – In Vitro Mts Assay for Measuring the Cytotoxic Effect of Nanoparticles*, ISO, Geneva, Switzerland, 2018.
- 52 R. T. Eastman, J. S. Roth, K. R. Brimacombe, A. Simeonov, M. Shen, P. Sa Marjit and M. D. Hall, *ACS Cent. Sci.*, 2020, **6**, 672–683.
- 53 M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong and G. Xiao, *Cell Res.*, 2020, **30**, 269–271.
- 54 L. Chen and J. Liang, *Mater. Sci. Eng., C*, 2020, **112**, 110924.
- 55 A. Barras, Q. Pagneux, F. Sane, Q. Wang, R. Boukherroub, D. Hober and S. Szunerits, *ACS Appl. Mater. Interfaces*, 2016, **8**, 9004–9013.
- 56 S. Huang, J. Gu, J. Ye, B. Fang, S. Wan, C. Wang, U. Ashraf, Q. Li, X. Wang, L. Shao, Y. Song, X. Zheng, F. Cao and S. Cao, *J. Colloid Interface Sci.*, 2019, **542**, 198–206.
- 57 T. Cowen, A. J. Haven, G. Burnstock and G. Pontamine, *Histochemistry*, 1985, **82**, 205–208.
- 58 J. A. Lynch and J. B. Derbyshire, *Can. J. Vet. Res.*, 1986, **50**, 384–389.
- 59 S. Salatin and A. Y. Khosroushahi, *J. Cell. Mol. Med.*, 2017, **21**, 1668–1686.
- 60 A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire and D. Veessler, *Cell*, 2020, **181**, 281–292.
- 61 E. Joonaki, A. Hassanpouryouzband, C. L. Heldt and O. Areo, *Chem*, 2020, **6**, 2135–2146.
- 62 B. Michen and T. Graule, *J. Appl. Microbiol.*, 2010, **109**, 388–397.
- 63 S. Kotta, H. M. Aldawsari, S. M. Badr-Eldin, N. A. Alhakamy, S. Md and A. B. Nair, *Front. Mol. Biosci.*, 2020, **7**, 428.

